WVU Cancer Institute participates in groundbreaking study on new cancer drug

WVU Cancer Institute participates in groundbreaking study on new cancer drug

Clinical data reported in New England Journal of Medicine

MORGANTOWN, W.Va. – The WVU Cancer Institute is one of several sites nationwide that participated in a groundbreaking clinical research study of a novel drug proven very effective in the treatment of pediatric and adult cancers that carry a specific genetic mutation.

Larotrectinib, developed by biopharmaceutical company Loxo Oncology, was tested in three clinical research studies at cancer centers nationwide. Patients ranged in age from four months to 76 years and had a total of 12 different tumor types, including common and rare cancers, but all had the genetic mutation in the NTRK gene in common.

Seventy-five to 80 percent of the 55 adult and pediatric patients treated with larotrectinib experienced significant tumor reductions with only mild side effects, regardless of patients’ age and specific tumor types. One patient with infantile fibrosarcoma responded so well to the test drug that limb amputation surgery was no longer necessary as part of the child’s treatment plan.

“This study demonstrated the principle of genomically targeted therapy and represents a possible paradigm change in treatment for these patients,” Patrick Ma, M.D., principal investigator of the WVU Cancer Institute study, said. “Larotrectnib works by seeking out the NTRK cancer gene that is activated by a form of gene fusion in these cancers and prevents its ability to promote cancer growth.”

Patients enrolled in the study had TRK fusion cancers caused by NTRK gene mutations that were detected through molecular profiling, a technology that allows clinicians to determine the genomic make-up and origin of cancer and its specific drug responsiveness to inform cancer treatment.

“Importantly, TRK fusion cancers occur in less than one percent of cancers but can be found in more than 20 cancer types,” Dr. Ma said. “Identifying these unique, genomically altered orphan cancers becomes crucially important with highly effective targeted therapy available that can make a real difference in treatment outcomes. With the help of comprehensive molecular profiling, we not only can identify and match patients to optimal therapies, but can also better understand changes in tumor cells throughout treatment and offer patients more personalized therapy.”

Ma is director of the Clinical Lung Cancer Program and co-leader of the Sara Crile Allen and James Frederick Allen Lung Cancer Program at the WVU Cancer Institute. He is co-author of the article "Efficacy of larotrectinib in TRK fusion-positive adult and pediatric cancers," which was published in the Feb. 22 issue of the New England Journal of Medicine.

For more information: Amy Johns, Director of Public Affairs, 304-285-7264
  • Dr. Martinez presents research at Gottingen University-Max Planck Institutes in Germany, collaborations with Cancer Institute to follow

    Dr. Martinez presents research at Gottingen University-Max Planck Institutes in Germany, collaborations with Cancer Institute to follow

    WVU Cancer Institute’s Dr. Ivan Martinez and his lab will engage in collaborative research with their colleagues at The German Primate Center, part of the Gottingen University-Max Planck Institutes in Germany, later this year.

    Read More

  • School board donation to benefit cancer research

    School board donation to benefit cancer research

    The Monongalia County Board of Education has made a donation to the WVU Cancer Institute to support clinical research.

    Read More

  • Rally builds excitement for Relay

    Rally builds excitement for Relay

    WVU Cancer Institute and WVU Medicine faculty, staff and students are gearing up for the 2018 American Cancer Society Monongalia County Relay For Life in June. During a Relay rally this past Friday in the Cancer Center Atrium, Cancer Institute Director Rich Goldberg, MD, told rally participants that the Cancer Institute has had a great relationship with the American Cancer Society over the years. “The ACS has provided services to our patients and funding to support our cancer research,” Dr. Goldberg said. He urged rally participants to join him in walking around the track at the Relay on June 8-9 at Westwood Middle School in Morgantown and asked that they recruit others to participate. Mary Lough of the ACS presented Dr. Goldberg a crystal award for the Cancer Institute’s presenting sponsorship of last year’s Relay. Roger Williams and Lisa Keller of the inpatient pharmacy at Ruby Memorial received a ruby slippers award from Relay For Life Event Ambassador Dave Staten. Their Ruby Slippers team raised $5,000 for the 2017 Relay, the most raised by any Relay team in Monongalia County.

    Read More